HPV 관련 질환 시장 규모, 점유율 및 동향 분석 보고서 : 유형별, 치료법별, 유통 채널별, 지역별 및 부문별 예측(2026-2033년)

HPV Associated Disorders Market Summary

The global HPV associated disorders market size was valued at USD 19.4 billion in 2025 and is projected to grow from USD 20.4 billion to USD 28.5 billion by 2033, at a CAGR of 4.9% from 2026 to 2033. North America HPV associated disorders market held the largest share of 37.4% of the global market in 2025. Persistent HPV infections continue to represent a major clinical and economic burden within the HPV associated disorders market, as they are strongly linked to cervical, anal, vulvar, vaginal, penile, and oropharyngeal cancers.

The increasing incidence of HPV-driven malignancies is accelerating demand for early and accurate diagnostic solutions across healthcare systems globally. As a result, molecular diagnostic technologies capable of detecting high-risk HPV strains, particularly HPV-16 and HPV-18, are witnessing rising adoption in hospitals, cancer centers, and specialized laboratories. Healthcare authorities are also strengthening organized screening initiatives to improve early identification of precancerous lesions and reduce long-term cancer burden. In addition, growing awareness regarding HPV-associated cancers and rising implementation of HPV-first screening protocols are supporting higher testing volumes across developed and emerging healthcare markets. These trends continue to reinforce the importance of preventive diagnostics and timely disease management within the global HPV associated disorders market landscape.

Advancements in treatment solutions are emerging as another major growth driver for the HPV associated disorders market, particularly with increasing development of immunotherapies, targeted oncology drugs, and precision medicine approaches for HPV-related malignancies. Pharmaceutical and biotechnology companies are expanding research and development investments to strengthen the therapeutic pipeline and improve treatment outcomes for patients with persistent HPV-associated cancers. Clinical studies evaluating immune checkpoint inhibitors, therapeutic vaccines, and biomarker-driven therapies are yielding encouraging results in terms of progression-free survival and reduced recurrence. In addition, rising focus on personalized oncology treatment strategies is contributing to broader adoption of targeted therapies for cervical and head & neck cancers linked to HPV infection. These innovations are addressing unmet clinical needs while improving long-term disease management and patient quality of life, thereby creating significant growth opportunities for companies operating within the HPV associated disorders treatment landscape.

For instance, in April 2025, authors at BioMed Central Ltd. reported that human papillomavirus (HPV), a DNA virus, had been established as a causative agent of cervical, vulvar, vaginal, penile, anal, and head & neck cancers. The study highlighted that persistent infection and the oncogenic activity of specific HPV genotypes were responsible for the majority of HPV-related malignancies worldwide. High-risk strains such as HPV-16 and HPV-18 were reported to account for more than 70% of cervical cancer cases globally, while also contributing significantly to genital and oropharyngeal cancers. At the molecular level, the study identified overexpression of E6 and E7 oncoproteins as a key mechanism disrupting cell-cycle regulation and promoting malignant transformation. The review further emphasized recent advancements involving biomarkers, including mRNAs, miRNAs, lncRNAs, proteins, and genetic markers, for monitoring therapeutic response and supporting precision oncology approaches in HPV-related cancer management.

Global HPV Associated Disorders Market Report Segmentation

This report forecasts revenue growth at global, regional, and country levels and provides an analysis of the latest industry trends in each of the sub-segments from 2021 to 2033. For this study, Grand View Research has segmented the global HPV associated disorders market report based on type, treatment, distribution channel, and region:

• Type Outlook (Revenue, USD Billion, 2021 - 2033)
• Cervical Intraepithelial Neoplasia (CIN)
• Cervical Cancer
• Anal Intraepithelial Neoplasia (AIN)
• Anal Cancer
• Genital Warts
• Others
• Treatment Outlook (Revenue, USD Billion, 2021 - 2033)
• Vaccines
• Anti-viral Drugs
• Others
• Distribution Channel Outlook (Revenue, USD Billion, 2021 - 2033)
• Hospital Pharmacies
• Retail Pharmacies
• Others
• Regional Outlook (Revenue, USD Billion, 2021 - 2033)
• North America
  • U.S.
  • Canada
  • Mexico
• Europe
  • UK
  • Germany
  • France
  • Italy
  • Spain
  • Denmark
  • Sweden
  • Norway
• Asia Pacific
  • Japan
  • China
  • India
  • Australia
  • South Korea
  • Thailand
• Latin America
  • Brazil
  • Argentina
• Middle East & Africa
  • South Africa
  • Saudi Arabia
  • UAE
  • Kuwait

Table of Contents

Chapter 1. Methodology and Scope

• 1.1. Market Segmentation & Scope
• 1.2. Segment Definitions
  • 1.2.1. Type
  • 1.2.2. Treatment
  • 1.2.3. Distribution Channel
• 1.3. Estimates and Forecast Timeline
• 1.4. Research Methodology
• 1.5. Information Procurement
  • 1.5.1. Purchased Database
  • 1.5.2. GVR's Internal Database
  • 1.5.3. Secondary Sources
  • 1.5.4. Primary Research
• 1.6. Information Analysis
  • 1.6.1. Data Analysis Models
• 1.7. Market Formulation & Data Visualization
• 1.8. Model Details
  • 1.8.1. Commodity Flow Analysis
• 1.9. List of Secondary Sources
• 1.10. Objectives

Chapter 2. Executive Summary

• 2.1. Market Snapshot
• 2.2. Segment Snapshot
• 2.3. Competitive Landscape Snapshot

Chapter 3. HPV Associated Disorders Market Variables, Trends, & Scope

• 3.1. Market Lineage Outlook
• 3.2. Market Dynamics
  • 3.2.1. Market Driver Analysis
  • 3.2.2. Market Restraint Analysis
• 3.3. Business Environment Analysis
  • 3.3.1. Industry Analysis - Porter's Five Forces Analysis
    • 3.3.1.1. Supplier Power
    • 3.3.1.2. Buyer Power
    • 3.3.1.3. Substitution Threat
    • 3.3.1.4. Threat of New Entrants
    • 3.3.1.5. Competitive Rivalry
  • 3.3.2. PESTLE Analysis
  • 3.3.3. Pipeline Analysis
  • 3.3.4. Patent Expiry Analysis
  • 3.3.5. Pricing Analysis

Chapter 4. HPV Associated Disorders Market: Type Business Analysis

• 4.1. Type Market Share, 2025 & 2033
• 4.2. Type Segment Dashboard
• 4.3. Market Size & Forecasts and Trend Analysis, by Type, 2021 to 2033 (USD Billion)
• 4.4. Cervical Intraepithelial Neoplasia (CIN)
  • 4.4.1. Cervical Intraepithelial Neoplasia (CIN) Market, 2021 - 2033 (USD Billion)
• 4.5. Cervical Cancer
  • 4.5.1. Cervical Cancer Market, 2021 - 2033 (USD Billion)
• 4.6. Anal Intraepithelial Neoplasia (AIN)
  • 4.6.1. Anal Intraepithelial Neoplasia (AIN) Market, 2021 - 2033 (USD Billion)
• 4.7. Anal Cancer
  • 4.7.1. Anal Cancer Market, 2021 - 2033 (USD Billion)
• 4.8. Genital Warts
  • 4.8.1. Genital Warts Market, 2021 - 2033 (USD Billion)
• 4.9. Others
  • 4.9.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 5. HPV Associated Disorders Market: Treatment Business Analysis

• 5.1. Treatment Market Share, 2025 & 2033
• 5.2. Treatment Segment Dashboard
• 5.3. Market Size & Forecasts and Trend Analysis, by Treatment, 2021 to 2033 (USD Billion)
• 5.4. Vaccines
  • 5.4.1. Vaccines Market, 2021 - 2033 (USD Billion)
• 5.5. Anti-viral Drugs
  • 5.5.1. Anti-viral Drugs Market, 2021 - 2033 (USD Billion)
• 5.6. Others
  • 5.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 6. HPV Associated Disorders Market: Distribution Channel Business Analysis

• 6.1. Distribution Channel Market Share, 2025 & 2033
• 6.2. Distribution Channel Segment Dashboard
• 6.3. Market Size & Forecasts and Trend Analysis, by Distribution Channel, 2021 to 2033 (USD Billion)
• 6.4. Hospital Pharmacies
  • 6.4.1. Hospital Pharmacies Market, 2021 - 2033 (USD Billion)
• 6.5. Retail Pharmacies
  • 6.5.1. Retail Pharmacies Market, 2021 - 2033 (USD Billion)
• 6.6. Others
  • 6.6.1. Others Market, 2021 - 2033 (USD Billion)

Chapter 7. HPV Associated Disorders Market: Regional Estimates & Trend Analysis

• 7.1. Regional Market Share Analysis, 2025 & 2033
• 7.2. Regional Market Dashboard
• 7.3. Market Size & Forecasts Trend Analysis, 2021 to 2033:
• 7.4. North America
  • 7.4.1. North America HPV Associated Disorders Market Estimates and Forecasts, By Country, 2021 - 2033 (USD Billion)
  • 7.4.2. U.S.
    • 7.4.2.1. Key Country Dynamics
    • 7.4.2.2. Target Disease Prevalence
    • 7.4.2.3. Regulatory Framework
    • 7.4.2.4. Reimbursement Framework
    • 7.4.2.5. U.S. HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.3. Canada
    • 7.4.3.1. Key Country Dynamics
    • 7.4.3.2. Target Disease Prevalence
    • 7.4.3.3. Regulatory Framework
    • 7.4.3.4. Reimbursement Framework
    • 7.4.3.5. Canada HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.4.4. Mexico
    • 7.4.4.1. Key Country Dynamics
    • 7.4.4.2. Target Disease Prevalence
    • 7.4.4.3. Regulatory Framework
    • 7.4.4.4. Reimbursement Framework
    • 7.4.4.5. Mexico HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.5. Europe
  • 7.5.1. Europe HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.2. UK
    • 7.5.2.1. Key Country Dynamics
    • 7.5.2.2. Target Disease Prevalence
    • 7.5.2.3. Regulatory Framework
    • 7.5.2.4. Reimbursement Framework
    • 7.5.2.5. UK HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.3. Germany
    • 7.5.3.1. Key Country Dynamics
    • 7.5.3.2. Target Disease Prevalence
    • 7.5.3.3. Regulatory Framework
    • 7.5.3.4. Reimbursement Framework
    • 7.5.3.5. Germany HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.4. France
    • 7.5.4.1. Key Country Dynamics
    • 7.5.4.2. Target Disease Prevalence
    • 7.5.4.3. Regulatory Framework
    • 7.5.4.4. Reimbursement Framework
    • 7.5.4.5. France HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.5. Italy
    • 7.5.5.1. Key Country Dynamics
    • 7.5.5.2. Target Disease Prevalence
    • 7.5.5.3. Regulatory Framework
    • 7.5.5.4. Reimbursement Framework
    • 7.5.5.5. Italy HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.6. Spain
    • 7.5.6.1. Key Country Dynamics
    • 7.5.6.2. Target Disease Prevalence
    • 7.5.6.3. Regulatory Framework
    • 7.5.6.4. Reimbursement Framework
    • 7.5.6.5. Spain HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.7. Denmark
    • 7.5.7.1. Key Country Dynamics
    • 7.5.7.2. Target Disease Prevalence
    • 7.5.7.3. Regulatory Framework
    • 7.5.7.4. Reimbursement Framework
    • 7.5.7.5. Denmark HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.8. Sweden
    • 7.5.8.1. Key Country Dynamics
    • 7.5.8.2. Target Disease Prevalence
    • 7.5.8.3. Regulatory Framework
    • 7.5.8.4. Reimbursement Framework
    • 7.5.8.5. Sweden HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.5.9. Norway
    • 7.5.9.1. Key Country Dynamics
    • 7.5.9.2. Target Disease Prevalence
    • 7.5.9.3. Regulatory Framework
    • 7.5.9.4. Reimbursement Framework
    • 7.5.9.5. Norway HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.6. Asia Pacific
  • 7.6.1. Asia Pacific HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.2. Japan
    • 7.6.2.1. Key Country Dynamics
    • 7.6.2.2. Target Disease Prevalence
    • 7.6.2.3. Regulatory Framework
    • 7.6.2.4. Reimbursement Framework
    • 7.6.2.5. Japan HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.3. China
    • 7.6.3.1. Key Country Dynamics
    • 7.6.3.2. Target Disease Prevalence
    • 7.6.3.3. Regulatory Framework
    • 7.6.3.4. Reimbursement Framework
    • 7.6.3.5. China HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.4. India
    • 7.6.4.1. Key Country Dynamics
    • 7.6.4.2. Target Disease Prevalence
    • 7.6.4.3. Regulatory Framework
    • 7.6.4.4. Reimbursement Framework
    • 7.6.4.5. India HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.5. Australia
    • 7.6.5.1. Key Country Dynamics
    • 7.6.5.2. Target Disease Prevalence
    • 7.6.5.3. Regulatory Framework
    • 7.6.5.4. Reimbursement Framework
    • 7.6.5.5. Australia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.6. South Korea
    • 7.6.6.1. Key Country Dynamics
    • 7.6.6.2. Target Disease Prevalence
    • 7.6.6.3. Regulatory Framework
    • 7.6.6.4. Reimbursement Framework
    • 7.6.6.5. South Korea HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.6.7. Thailand
    • 7.6.7.1. Key Country Dynamics
    • 7.6.7.2. Target Disease Prevalence
    • 7.6.7.3. Regulatory Framework
    • 7.6.7.4. Reimbursement Framework
    • 7.6.7.5. Thailand HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.7. Latin America
  • 7.7.1. Latin America HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7.2. Brazil
    • 7.7.2.1. Key Country Dynamics
    • 7.7.2.2. Target Disease Prevalence
    • 7.7.2.3. Regulatory Framework
    • 7.7.2.4. Reimbursement Framework
    • 7.7.2.5. Brazil HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.7.3. Argentina
    • 7.7.3.1. Key Country Dynamics
    • 7.7.3.2. Target Disease Prevalence
    • 7.7.3.3. Regulatory Framework
    • 7.7.3.4. Reimbursement Framework
    • 7.7.3.5. Argentina HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
• 7.8. Middle East and Africa
  • 7.8.1. Middle East and Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.2. South Africa
    • 7.8.2.1. Key Country Dynamics
    • 7.8.2.2. Target Disease Prevalence
    • 7.8.2.3. Regulatory Framework
    • 7.8.2.4. Reimbursement Framework
    • 7.8.2.5. South Africa HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.3. Saudi Arabia
    • 7.8.3.1. Key Country Dynamics
    • 7.8.3.2. Target Disease Prevalence
    • 7.8.3.3. Regulatory Framework
    • 7.8.3.4. Reimbursement Framework
    • 7.8.3.5. Saudi Arabia HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.4. UAE
    • 7.8.4.1. Key Country Dynamics
    • 7.8.4.2. Target Disease Prevalence
    • 7.8.4.3. Regulatory Framework
    • 7.8.4.4. Reimbursement Framework
    • 7.8.4.5. UAE HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)
  • 7.8.5. Kuwait
    • 7.8.5.1. Key Country Dynamics
    • 7.8.5.2. Target Disease Prevalence
    • 7.8.5.3. Regulatory Framework
    • 7.8.5.4. Reimbursement Framework
    • 7.8.5.5. Kuwait HPV Associated Disorders Market Estimates and Forecasts, 2021 - 2033 (USD Billion)

Chapter 8. Competitive Landscape

• 8.1. Participant Overview
• 8.2. Company Market Position Analysis
• 8.3. Company Categorization
• 8.4. Strategy Mapping
• 8.5. Company Profiles/Listing
  • 8.5.1. Merck & Co., Inc.
    • 8.5.1.1. Overview
    • 8.5.1.2. Financial Performance
    • 8.5.1.3. Product Benchmarking
    • 8.5.1.4. Strategic Initiatives
  • 8.5.2. GlaxoSmithKline plc
    • 8.5.2.1. Overview
    • 8.5.2.2. Financial Performance
    • 8.5.2.3. Product Benchmarking
    • 8.5.2.4. Strategic Initiatives
  • 8.5.3. F. Hoffmann-La Roche Ltd
    • 8.5.3.1. Overview
    • 8.5.3.2. Financial Performance
    • 8.5.3.3. Product Benchmarking
    • 8.5.3.4. Strategic Initiatives
  • 8.5.4. Pfizer Inc.
    • 8.5.4.1. Overview
    • 8.5.4.2. Financial Performance
    • 8.5.4.3. Product Benchmarking
    • 8.5.4.4. Strategic Initiatives
  • 8.5.5. AstraZeneca
    • 8.5.5.1. Overview
    • 8.5.5.2. Financial Performance
    • 8.5.5.3. Product Benchmarking
    • 8.5.5.4. Strategic Initiatives
  • 8.5.6. Biocon
    • 8.5.6.1. Overview
    • 8.5.6.2. Financial Performance
    • 8.5.6.3. Product Benchmarking
    • 8.5.6.4. Strategic Initiatives
  • 8.5.7. Lilly
    • 8.5.7.1. Overview
    • 8.5.7.2. Financial Performance
    • 8.5.7.3. Product Benchmarking
    • 8.5.7.4. Strategic Initiatives
  • 8.5.8. AbbVie Inc.
    • 8.5.8.1. Overview
    • 8.5.8.2. Financial Performance
    • 8.5.8.3. Product Benchmarking
    • 8.5.8.4. Strategic Initiatives